ConductScience.org, home

Paper42876375PubMed

Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab.

Kaneko S and 10 others. Thorac Cancer, 2026.

Cite this record

ConductScience Library. Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab. Papers, record 42876375. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42876375

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab.
Journal
Thorac Cancer
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-17

Source PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kaneko SShotaro
2Furuya NNaokihttps://orcid.org/0000-0001-7162-5946
3Sugiura YYoshihisahttps://orcid.org/0000-0002-0155-9645
4Tsuruoka HHajimehttps://orcid.org/0009-0002-3624-9409
5Nishiyama KKazuhirohttps://orcid.org/0009-0006-9673-9820
6Morita HHonoka
7Okura TTomoki
8Saji HHisashihttps://orcid.org/0000-0003-3490-7658
9Koike JJunkihttps://orcid.org/0000-0001-9026-244X
10Ohike NNobuyukihttps://orcid.org/0000-0001-8631-821X
11Mineshita MMasamichihttps://orcid.org/0000-0002-6933-6579

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Membrane ProteinsMajor topic
Intracellular Signaling Peptides and ProteinsMajor topic
Lymphocytes, Tumor-InfiltratingMajor topic
Carcinoma, NeuroendocrineMajor topic
Lung NeoplasmsMajor topic
Carcinoma, Large CellMajor topic
Humans
Female
Male
Aged
Prognosis
Retrospective Studies
Aged, 80 and over
Middle Aged
CD8-Positive T-Lymphocytes
Antibodies, Bispecific

Source PubMed

Download CSV of topics

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129378266Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.J Thorac Oncol2018https://conductscience.org/library/papers/29378266PubMed
235983951DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.Oncologist2022https://conductscience.org/library/papers/35983951PubMed
331678831DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.Lung Cancer2019https://conductscience.org/library/papers/31678831PubMed
439309421Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report.JTO Clin Res Rep2024https://conductscience.org/library/papers/39309421PubMed
531903172Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis.Oncotarget2019https://conductscience.org/library/papers/31903172PubMed
632691982DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.Thorac Cancer2020https://conductscience.org/library/papers/32691982PubMed
723208313Investigation of the freely available easy-to-use software 'EZR' for medical statistics.Bone Marrow Transplant2013https://conductscience.org/library/papers/23208313PubMed
837930513Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer.Target Oncol2023https://conductscience.org/library/papers/37930513PubMed
933859752Turning cold tumors into hot tumors by improving T-cell infiltration.Theranostics2021https://conductscience.org/library/papers/33859752PubMed
1040284515Targeting DLL3: Innovative Strategies for Tumor Treatment.Pharmaceutics2025https://conductscience.org/library/papers/40284515PubMed
1134808341The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.J Thorac Oncol2022https://conductscience.org/library/papers/34808341PubMed
1239372398Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis.Front Immunol2024https://conductscience.org/library/papers/39372398PubMed
1340440602Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies.Am Soc Clin Oncol Educ Book2025https://conductscience.org/library/papers/40440602PubMed
1440706016
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.
J Clin Oncol2025https://conductscience.org/library/papers/40706016PubMed
1533482121Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.Cancer Cell2021https://conductscience.org/library/papers/33482121PubMed
1637114477Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.Expert Rev Anticancer Ther2023https://conductscience.org/library/papers/37114477PubMed
1730885341Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).Lung Cancer2019https://conductscience.org/library/papers/30885341PubMed
1832745892International real-world study of DLL3 expression in patients with small cell lung cancer.Lung Cancer2020https://conductscience.org/library/papers/32745892PubMed
1931087628The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung.Cancer Med2019https://conductscience.org/library/papers/31087628PubMed
2036689692Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.J Clin Oncol2023https://conductscience.org/library/papers/36689692PubMed

See all 36 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42876375

GET https://conductscience.org/api/papers/v1/42876375/references?page=2